M. Schneider

7.8k total citations · 2 hit papers
108 papers, 5.8k citations indexed

About

M. Schneider is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, M. Schneider has authored 108 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 23 papers in Otorhinolaryngology. Recurrent topics in M. Schneider's work include Head and Neck Cancer Studies (23 papers), Acute Lymphoblastic Leukemia research (14 papers) and Lung Cancer Treatments and Mutations (12 papers). M. Schneider is often cited by papers focused on Head and Neck Cancer Studies (23 papers), Acute Lymphoblastic Leukemia research (14 papers) and Lung Cancer Treatments and Mutations (12 papers). M. Schneider collaborates with scholars based in France, Belgium and United Kingdom. M. Schneider's co-authors include G. Milano, F Démard, Antoine Thyss, L Schwarzenberg, Jeanne Amiel, O. Dassonville, M C Etienne, A Cattan, N. Renée and G Mathé and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

M. Schneider

105 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients

2004 678 citations M. Schneider et al. profile →
ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIA

1969 452 citations G Mathé, Jeanne Amiel et al. The Lancet profile →

Peers

Countries citing papers authored by M. Schneider

Since Specialization

Citations

This map shows the geographic impact of M. Schneider's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Schneider with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Schneider more than expected).

Fields of papers citing papers by M. Schneider

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Schneider. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Schneider. The network helps show where M. Schneider may publish in the future.

Co-authorship network of co-authors of M. Schneider

This figure shows the co-authorship network connecting the top 25 collaborators of M. Schneider. A scholar is included among the top collaborators of M. Schneider based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Schneider. M. Schneider is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	[Current therapeutic strategy for rheumatoid arthritis]. 2006 ·PubMed ·J. Wollenhaupt, R. Alten, Harald Burkhardt, (unknown), Erika Gromnica‐Ihle, (unknown), K. Krüger, Bernhard Manger, Hanns‐Martin Lorenz, Ulf Müller‐Ladner, (unknown), (unknown), Hans‐Peter Tony, M. Schneider	3
2	Anémie et cancers des voies aérodigestives supérieures 2005 ·Bulletin du Cancer ·D. Azria, Abderrahim Zouhair, (unknown), C. Lemanski, M. Schneider, Mahmut Özsahin, (unknown), Éric Lartigau	3
3	Predicting dihydropyrimidine deshydrogenase (DPD) deficiency in cancer patients: Enzymatic activity in lymphocytes vs uracil/dihydrouracil (U/UH2) ratio determination in plasma 2005 ·Cancer Research ·Joseph Ciccolini, Marie-Christine Étienne-Grimaldi, N. Renée, Jean–Louis Formento, Pierre Cuq, M. Schneider, Bruno Lacarelle, G. Milano	2
4	Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer 2005 ·Oral Oncology ·Xavier Pivot, Nicolas Magné, Emmanuel Guardiola, G. Poissonnet, O. Dassonville, M Francoual, Jean–Louis Formento, René‐Jean Bensadoun, F Démard, M. Schneider, G. Milano	39
5	Phase III multicenter randomized study of concurrent twice-a-day radiotherapy with and without cisplatin-5FU (BiRCF) in unresectable pharyngeal carcinoma. 24 months results (FNCLCC-GORTEC) 2004 ·International Journal of Radiation OncologyBiologyPhysics ·René‐Jean Bensadoun, Karen Bénézery, A. Ramaioli, Nicolas Magné, C. Lemanski, J. Tortochaux, S. Bourdin, O. Dassonville, G. Milano, M. Schneider, G. Calais, F Démard	1
6	Comparison between nasogastric tube feeding and percutaneous fluoroscopic gastrostomy in advanced head and neck cancer patients 2001 ·European Archives of Oto-Rhino-Laryngology ·Nicolas Magné, Pierre‐Yves Marcy, Cyril Foa, M.-N. Falewee, M. Schneider, F Démard, René‐Jean Bensadoun	83
7	Radiothérapie bifractionnée et chimiothérapie par cisplatine et 5-fluoro-uracile concomitantes dans les carcinomes épidermoïdes localement évolués non résécables du pharynx : dix ans d’expérience au centre Antoine Lacassagne 2001 ·Cancer/Radiothérapie ·Nicolas Magné, Xavier Pivot, Pierre‐Yves Marcy, Patrick Chauvel, A. Courdi, O. Dassonville, G. Poissonnet, J Vallicioni, F. Ettore, M.-N. Falewee, G. Milano, J. Santini, (unknown), M. Schneider, F Démard, René‐Jean Bensadoun	1
8	Phase II Trial of a Paclitaxel-Carboplatin Combination in Recurrent Squamous Cell Carcinoma of the Head and Neck 2000 ·Oncology ·Xavier Pivot, L. Cals, Didier Cupissol, Emmanuel Guardiola, X. Tchiknavorian, (unknown), (unknown), J. L. Wendling, (unknown), J. Savary, Antoine Thyss, M. Schneider	33
9	Technique de gastrostomie percutanée radiologique : évaluation coût/bénéfice chez les patients porteurs d’un cancer des voies aérodigestives supérieures 2000 ·Bulletin du Cancer ·Pierre-Yves Marcy, Nicolas Magné, René‐Jean Bensadoun, (unknown), (unknown), O. Dassonville, G. Poissonnet, M. Schneider, F Démard, Jean-Noël Bruneton	4
10	Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. 1995 ·Journal of Clinical Oncology ·M. Schneider, M C Etienne, G. Milano, Antoine Thyss, Josiane Otto, O. Dassonville, (unknown), (unknown), Thierry Guillot, F Démard	49
11	Influence of sex and age on fluorouracil clearance. 1992 ·Journal of Clinical Oncology ·G. Milano, M C Etienne, E. Cassuto‐Viguier, Antoine Thyss, J. Santini, M. Frénay, N. Renée, M. Schneider, F Démard	213
12	Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas 1991 ·Head & Neck ·(unknown), (unknown), M Francoual, G. Milano, M. Schneider, O. Dassonville, F Démard	214
13	5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer 1989 ·British Journal of Cancer ·J. Santini, G. Milano, Antoine Thyss, N. Renée, Patrice Viens, (unknown), M. Schneider, F Démard	143
14	Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies 1987 ·European Journal of Cancer and Clinical Oncology ·A. Thyss, G. Milano, Anne Deville, (unknown), N. Renée, M. Schneider	25
15	Hydroxyurea, Leucopheresis, and Splenectomy in Chronic Myeloid Leukaemia at the Problastic Phase 1973 ·BMJ ·L Schwarzenberg, G Mathé, P Pouillart, Roy S. Weiner, (unknown), (unknown), M. Schneider, F. de Vassal, M. Hayat, Jeanne Amiel, Jean Schlumberger, C Jasmin, (unknown)	21
16	ACUTE LYMPHOBLASTIC LEUKÆMIA TREATED WITH A COMBINATION OF PREDNISONE, VINCRISTINE, AND RUBIDOMYCIN 1967 ·The Lancet ·G Mathé, Maham Hayat, L Schwarzenberg, Jeanne Amiel, M. Schneider, A Cattan, Jean Schlumberger, C Jasmin	46
17	[Immunological approaches to the treatment of human cancers]. 1967 ·PubMed ·G Mathé, L Schwarzenberg, Amiel Jl, M. Schneider, A Cattan, Schlumberger	1
18	ATTEMPTED ADOPTIVE IMMUNOTHERAPY OF ACUTE LEUKÆMIA BY LEUCOCYTE TRANSFUSIONS 1966 ·The Lancet ·L Schwarzenberg, G Mathé, M. Schneider, Jeanne Amiel, A Cattan, Jean Schlumberger	39
19	Haematopoietic Chimera in Man After Allogenic (Homologous) Bone-marrow Transplantation 1963 ·BMJ ·G Mathé, Jeanne Amiel, L Schwarzenberg, A Cattan, M. Schneider	98
20	METHYL-HYDRAZINE IN TREATMENT OF HODGKIN'S DISEASE AND VARIOUS FORMS OF HÆMATOSARCOMA AND LEUKÆMIA 1963 ·The Lancet ·G Mathé, O Schweisguth, M. Schneider, Jeanne Amiel, (unknown), (unknown), A Cattan, L Schwarzenberg	69

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact